Andrew Cook, MD, Discussed Exciting Clinical Trials Utilizing DART and Treatment De-Escalation in HPV+ OSCC

Video

CancerNetwork® sat down with Andrew Cook, MD, at the 2021 American Society for Radiation Oncology to talk about exciting trials in the head and neck space, including the phase 2 ORATER2 and phase 3 MC1675 trials.

At the 2021 American Society for Radiation Oncology, CancerNetwork® spoke with Andrew Cook, MD, from Henry Ford Health System, about the most exciting clinical research presented at the meeting. One such trial was the phase 2 ORATER2 study (NCT03210103), which set out to assess treatment de-escalation with radiotherapy vs trans-oral surgery (TORS) in patients with human papilloma virus (HPV)–positive oropharyngeal cancer. Additionally, he highlighted the phase 3 MC1675 trial (NCT02908477), examining de-escalated adjuvant radiation therapy in HPV-associated oropharyngeal cancer.

Transcript:

In the head and neck area, there are a lot of really [interesting studies] that are going on. Specifically, [there are] 2 de-escalation trials [that I’m] excited to hear about. One is from Daniel Ma, MD. He has a phase 3 dynamic adaptive radiation therapy trial [where] they’re really looking at the de-escalation of radiation therapy after TORS for patients with HPV-positive oropharynx cancer, as compared with standard of care adjuvant radiation doses. I’m excited to hear about that.1 Also, David Palma, MD, MSc, PhD, FRCPC is going to present his phase 2 ORATOR2 trial, which actually [includes] 2 different de-escalated arms in regard to radiation as well as a surgical arm.2 There’s a lot of cool stuff coming in the field there.

References

1. Ma DJ, Price K, Eric MJ, et al. Long-term results for MC1273, a phase II evaluation of de-escalated adjuvant radiation therapy for human papillomavirus associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC). Int J Radiat Oncol Biol Phys. 2021; 111 (suppl 3): S61. doi/10.1016/j.ijrobp.2021.07.155

2. Nichols AC, Lang P, Prisman E, et al. Treatment de-escalation for HPV-associated oropharyngeal squamous cell carcinoma with radiotherapy vs. trans-oral surgery (ORATOR2). Presented at the 2021 American Society For Radiation Oncology October 24-27. Virtual. Abstract CT01

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
An ongoing phase 1 trial seeks to prove XmAb819 as an effective treatment and ENPP3 as a plausible target in patients with relapsed or refractory RCC.
“The therapy is designed to prevent both CAR T-cell inactivation and to restore the anti-tumor immunity of the white blood cells that have gotten through the tumor,” said Marasco, MD, PhD.
Ongoing studies aim to combine base immunotherapy regimens with novel agents to potentially improve outcomes among patients with kidney cancer.
Investigators have found a way to reduce liver and biliary toxicity when targeting the molecule CAIX in patients with clear cell renal cell carcinoma.
Neoantigen-targeting vaccines resulted in an absence of recurrence in 9 patients with high-risk kidney cancer, according to David A. Braun, MD, PhD.
The Kidney Cancer Research Consortium may allow collaborators to form more mechanistic and scientifically driven efforts in the field.
Wayne A. Marasco, MD, PhD, stated that by targeting 2 molecules instead of 1, higher levels of tumor cell killing can be achieved in patients with clear cell renal cell carcinoma.
Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.
Related Content